Background: Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension. Methods: This 8-week, multicenter, double-blind, placebo-controlled trial assessed the efficacy, safety, and tolerability of eplerenone in eligible patients randomized to eplerenone 50, 100, or 400 mg once daily; eplerenone 25, 50, or 200 mg twice daily; spironolactone 50 mg twice daily; or placebo. The primary efficacy variable was the adjusted mean change in baseline to final visit for seated diastolic blood pressure (DBP). Results: Of 417 randomized patients, 409 were evaluated for efficacy. The adjusted mean change from baseline to final visit in seated and standing systolic blood pressure (SBP) and DBP was significantly greater (P Ͻ .05) in all eplerenone groups than in the placebo group. The adjusted mean change in 24-h ambulatory blood pressure monitor-
A
ldosterone, an effector hormone of the renin-angiotensin-aldosterone system (RAAS), plays a critical role in the development and progression of cardiovascular disease. [1] [2] [3] Aldosterone has been linked to hypertension, cardiac hypertrophy, cardiac and vascular fibrosis, and ventricular arrhythmias. 4 -9 Although angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists initially reduce aldosterone, the majority of patients treated chronically with these drugs experience incomplete suppression of aldosterone and increased serum aldosterone levels. 10, 11 Spironolactone, an aldosterone receptor antagonist, has traditionally been used as a potassium-and magnesium-sparing diuretic in the treatment of hypertension and congestive heart failure 1, 12, 13 or in the management of primary aldosteronism. Although the clinical importance of aldosterone receptor antagonists in the treatment of congestive heart failure and hypertension has been demonstrated with spironolactone, 1, 12, 13 its use has been limited by progestational and antiandrogenic side effects including gynecomastia, impotence, and menstrual abnormalities. 14 Eplerenone is a new selective aldosterone blocker that, in contrast to spironolactone, demonstrates a high degree of selectivity for the aldosterone receptor and a low-binding affinity for progesterone (Ͻ1%) and androgen receptors (0.1%). 15 The present study was designed to examine the safety, efficacy, and tolerability of eplerenone compared to spironolactone and placebo in patients with mild-to-moderate hypertension.
Methods

Study Design
A multicenter, randomized, double-blind, placebo lead-in, parallel group, dose-ranging study was conducted at 48 US sites in accordance with Good Clinical Practices and the Declaration of Helsinki. The study protocol was approved by appropriate Institutional Review Boards. All patients provided written informed consent before enrollment.
This study compared the safety, efficacy, and tolerability of eplerenone and placebo. Spironolactone was included as an aldosterone receptor antagonist positive control. The study consisted of: 1) a 2-week pretreatment screening period, 2) a 4-week single-blind placebo lead-in period, and 3) an 8-week double-blind treatment period. Qualified patients in the double-blind treatment period were randomized by a computer-generated schedule to 50, 100, or 400 mg of eplerenone administered once daily or in divided doses; 50 mg of spironolactone twice daily; or placebo.
Study Population
Study subjects were 21 through 80 years of age and had both seated, cuff-assessed diastolic blood pressure (DBP) Ն95 mm Hg and Ͻ114 mm Hg and a 24-h mean DBP Ն85 mm Hg determined by a 24-h ambulatory BP monitoring (ABPM) device. Medication compliance (Ն80%) during the single-blind placebo lead-in period was required to qualify for randomization.
Exclusion criteria included: 1) secondary, severe, or malignant hypertension with or without retinopathy; 2) regular use of systemic medications known to influence BP; 3) regular use of nonsteroidal anti-inflammatory drugs; 4) myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, angina pectoris, or intermittent claudication within the previous 6 months; 5) severe aortic or mitral valvular disease and cardiac arrhythmia requiring medical treatment or causing hemodynamically relevant disturbances; 6) hypertrophic cardiomyopathy or congestive heart failure requiring digoxin or diuretic therapy; 7) stroke or transient ischemic attack within the previous 6 months; 8) insulin-dependent diabetes mellitus; 9) acute or chronic hepatic disease; 10) serum creatinine Ͼ1.5 mg/dL or serum potassium Ͼ5.0 mEq/L; 11) history of alcohol or drug abuse; 12) known hypersensitivity to spironolactone or steroids; 13) use of any other investigational medication 30 days before this study; 14) night-shift employment; or 15) upper arm circumference Ͼ42 cm.
Study Assessments
A conventional mercury sphygmomanometer was used to measure both seated and standing BP at 4 h before morning dosing (trough). After a minimum of 5 min of rest in the seated position, BP was determined at 3-to 5-min intervals until no two consecutive measurements of DBP differed by more than 6 mm Hg. After a minimum of 5 min in the standing position, BP was determined twice at 3-to 5-min intervals. Blood pressure was also measured during a 24-h period (ABPM), using portable monitors (model 90207, SpaceLabs, Inc., Bellevue, WA) that provided readings at 15-min intervals from 5 AM until 9:59 PM and 20-min intervals from 10 PM to 4:59 AM. The accuracy of the monitors was validated by cross-checking with a Ttube. Both sphygmomanometer cuff-assessed BP and ABPM were determined to be within 7 mm Hg during three consecutive DBP readings. The ABPM measurements were made for 24 h after the dose at the end of the placebo lead-in period and after 8 weeks of randomized therapy. The primary efficacy variable was the adjusted mean change from baseline in seated and standing, cuff-assessed DBP, measured at trough compared to placebo. Secondary efficacy variables included the adjusted mean change from baseline in seated, cuff-assessed systolic blood pressure (SBP); 24-h ABPM mean SBP and DBP; total and active plasma renin; and serum aldosterone levels. The primary and secondary efficacy variables were analyzed to compare twice daily dosing versus daily dosing regimens in each eplerenone dose group, and to compare both eplerenone and spironolactone versus placebo. 
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Statistical Methods
A sample size of 50 patients per group was planned to provide 80% power to detect a mean difference of 4.5 mm Hg in cuff DBP between each eplerenone dose group and the placebo group after 8 weeks of treatment. For this calculation, it was assumed that the standard deviation in cuff DBP changes at trough levels (before the morning dose) would be 8 mm Hg, and that each eplerenone dose group would be compared to placebo. The intent-to-treat population included all patients who had at least one evaluation in addition to the baseline evaluation. All analyses were two-tailed at the P Ͻ .05 level. Treatment groups were compared for continuous variables using a two-way analysis of variance (ANOVA) including treatment and investigator as factors. Pearson 2 tests were used to evaluate categorical data such as gender and ethnicity. The change from baseline in cuff-assessed DBP measured at 8 weeks or the final visit was evaluated using an analysis of covariance (ANCOVA), which included treatment and center as factors and baseline DBP as the covariate. Specific dosage comparisons within primary and secondary measures of efficacy were made using contrast-based t tests within a linear model.
Changes from baseline in RAAS hormonal data were analyzed using ANCOVA. Pairwise comparisons based on the linear trend-testing approach were replaced with conventional pairwise comparisons, as it could not be assumed that changes from baseline in RAAS hormonal profiles would exhibit a monotonic dose-response relationship. Placebo versus eplerenone comparisons were performed using Dunnett's test (two-tailed ␣ ϭ 0.05). Additional pairwise comparisons were performed using contrast-based t tests. Because the difference between baseline and final visit in total and active plasma renin was heavily skewed, analyses were done on log-transformed values.
All randomized patients who took at least one dose of study medication were included in the safety analyses. Adverse events were categorized by body system and preferred term using a modified version of the World Health Organization Adverse Reaction Terminology dictionary. Changes in adverse events from baseline to end of study were evaluated within treatment group using paired t tests and compared among treatment groups using Kruskal-Wallis tests.
Results
Patient Disposition
Overall, 417 patients were randomized to receive at least one dose of study medication and were subsequently included in the safety analyses. Of these, 409 had at least one evaluation after their baseline evaluation and were included in the efficacy analyses. Five patients were excluded because of protocol noncompliance and three were lost to follow-up. An additional 39 patients did not complete the study because of treatment failure (7), loss to follow-up (2), protocol noncompliance (16), pre-existing protocol violation (3), or adverse events (11) . No significant differences were noted among treatment groups with regard to baseline demographic or clinical characteristics (Table 1) . 
Blood Pressure Analyses
Reductions (P Ͻ .041) in mean seated and standing SBP and DBP from baseline to final visit were demonstrated in all eplerenone-treated groups compared to placebo except in standing DBP in the daily 100-mg eplerenone group. The mean change from baseline to final visit for eplerenone versus placebo in seated SBP ranged (in a dose-response manner) from Ϫ4.4 to Ϫ15.0 mm Hg and in seated DBP from Ϫ4.4 to Ϫ8.9 mm Hg (Fig. 1) .
The mean change from baseline to final visit in eplerenone versus placebo in standing SBP ranged from Ϫ3.6 to Ϫ14.5 mm Hg and in standing DBP ranged from Ϫ3.7 to Ϫ8.0 mm Hg. Except for greater reductions in seated and standing DBP in the twice daily 50-mg eplerenone group compared to the daily 100-mg eplerenone group (P ϭ .036 seated, P ϭ .012 standing), there were no significant differences between twice daily and daily dosing regimens.
Adjusted mean ABPM SBP was reduced by 6.2 to 16.1 mm Hg, and adjusted mean ABPM DBP was reduced by 4.1 to 9.0 mm Hg among eplerenone-treated patients between baseline and final visit. Significant reductions in SBP and DBP were seen in 24-h ABPM for all eplerenone doses used (Fig. 2) .
Trough measurements of ABPM SBP (the last 4-h segment of the 24-h ABPM measurement) were lowered by 5.2 to 20.4 mm Hg, and trough measurements of ABPM DBP were reduced by 4.1 to 12.1 mm Hg. Reductions (P Յ .011) compared to placebo were observed across all but two eplerenone groups in mean change from baseline to final visit in trough ABPM DBP measurements (Fig. 3) . Trough DBP after administration of 50 mg daily of eplerenone and trough DBP after administration of twice daily of 25 mg of eplerenone were not significantly different from placebo. No significant differences were observed between the twice daily and daily dosing regimens in ambulatory SBP and DBP measurements, except for a difference (P Ͻ .033) between the twice daily 200-mg and the daily 400-mg eplerenone dosing regimens for both SBP and DBP (SBP data not shown).
Spironolactone caused reductions (P Յ .001) in SBP and DBP compared to placebo (Figs. 1-3) . In general, adjusted mean changes from baseline to final visit in SBP and DBP for twice daily 50 mg and daily 100 mg of eplerenone dosing were approximately 50% to 75% of those observed with the twice daily 50-mg spironolactone group (Figs. 1-3) .
No significant differences in mean heart rate or mean change in heart rate from baseline were noted between any treatment groups. The mean change in heart rate from baseline ranged from Ϫ1.7 to 2.0 beats/min.
RAAS Hormone Profile
Differences in adjusted mean changes from baseline to final visit were observed in total plasma renin between all Table 2 . Mean adjusted change in serum aldosterone, total plasma renin, and active plasma renin doses of eplerenone and placebo (P Յ .05). Adjusted mean changes in total plasma renin levels differed between twice daily 50 mg and daily 100 mg of eplerenone (P Յ .025) and between twice daily 200 mg and daily 400 mg of eplerenone (P Յ .008) ( Table 2 ). Adjusted mean changes from baseline to final visit in active plasma renin levels of patients receiving twice daily 50 or 200 mg and daily 400 mg of eplerenone differed (P Յ .05) compared to placebo, but not between twice daily and daily eplerenone regimens. Between baseline and final visit, spironolactone increased both total and active plasma renin levels. Adjusted mean changes from baseline to final visit in total and active plasma renin levels were greater (P Ͻ .001) in the spironolactone group compared to placebo. With the exception of the twice daily 200-mg eplerenone group, all increases in total plasma renin were smaller in eplerenonetreated groups than in those receiving spironolactone. Differences (P Յ .05) in adjusted mean changes from baseline in total plasma renin levels were observed in the twice daily 25-mg, daily 50-mg, and daily 100-mg eplerenone groups compared to the twice daily 50-mg spironolactone group. Active plasma renin levels were lower in the twice daily 25-mg, daily 50-mg, and daily 100-mg eplerenone groups compared to the spironolactone group. A difference (P Յ .05) in adjusted mean change from baseline in active plasma renin levels was noted in the twice daily 25-mg eplerenone group compared to the spironolactone group.
Increases in serum aldosterone levels, observed in all eplerenone groups, were significant (P Յ .05) in the twice daily 50-and 200-mg eplerenone and the daily 100-and 400-mg eplerenone groups compared to placebo. The only difference among eplerenone groups was an increase (P Ͻ .001) in aldosterone levels after administering twice daily 200 mg of eplerenone versus daily 400 mg of eplerenone. Aldosterone levels were increased (P Ͻ .001) in spironolactone compared to placebo. Increases in aldosterone levels in the twice daily 25-and 50-mg eplerenone and daily 50-and 100-mg eplerenone groups were less than those observed in the twice daily 50-mg spironolactone group. Although increases in aldosterone levels were greater in the twice daily 200-mg eplerenone group than in the twice daily 50-mg spironolactone group, they were comparable in the daily 400-mg eplerenone and spironolactone groups. Aldosterone levels increased in the twice daily 25-and 50-mg and daily 50-mg eplerenone groups and were less (P Յ .05) than in the spironolactone-treated group. Aldosterone levels were greater (P Յ .05) in the twice daily 200-mg eplerenone group than in the twice daily 50-mg spironolactone group. (4) 1 (2) 1 (2) 5 (9) 3 (6) 6 (13) 1 (2) Sinusitus 0 0 4 (8) 0 1 (2) 3 (6) 1 (2) 1 (2) AE ϭ adverse event. 
Tolerability
Overall, 190 (46%) patients reported at least one adverse event, and 11 patients discontinued treatment because of adverse events. Most events were mild or moderate in severity. Only four were considered serious, of which one was considered drug-related. The incidence of adverse events in eplerenone-treated patients was similar to placebo (Table 3) . Two patients had DBP of Յ70 mm Hg, but neither observation was considered an adverse event.
The mean change in serum potassium levels from baseline was significant (P Ͻ .05) in the daily 400-mg eplerenone group; the twice daily 25-, 50-, and 100-mg eplerenone groups; and the spironolactone group (Table  4) . Seventeen patients (11 men and 6 women) had potassium levels Ն5.5 mEq/L, but changes in these levels were reported as adverse events for only one patient each in the placebo, and the daily 100-and 400-mg groups. It should be noted that no clinical symptoms were associated with these adverse events, and none of the 17 patients with serum potassium levels Ն5.5 mEq/L withdrew from the study.
No clinically relevant changes in liver function were reported in any treatment group. There were no reports of gynecomastia or an increased incidence of impotence in eplerenone-treated patients compared to placebo. No treatment-related menstrual abnormalities were reported, but one patient in the spironolactone group reported treatmentrelated intermenstrual bleeding. An increase (P Յ .05) in mean thyroid-stimulating hormone levels was observed in the daily 400-mg eplerenone group. No other eplerenone-, spironolactone-, or placebo-treated patients had clinically significant changes in thyroid-stimulating hormone levels or in other laboratory values.
Discussion
Eplerenone in daily doses of 50, 100, and 400 mg for 8 weeks significantly reduced BP compared to placebo. Eplerenone lowered BP in a dose-dependent manner by all measures with minimal effect on heart rate. Reductions in SBP were greater than those in DBP. The inclusion of spironolactone, an approved and marketed compound for the treatment of hypertension, as a positive control 14, 16 confirmed and validated the BP-lowering effects of eplerenone. A dose-response effect was observed in reducing both SBP and DBP with daily 50 and 400 mg of eplerenone, with 200 mg being optimal and with all doses significantly reducing BP. Finally, no consistent, clinically significant differences in lowering BP were noted between once-and twice-daily dosing regimens over the 8-week treatment period.
Blockade of aldosterone receptors by eplerenone resulted in dose-related increases in serum aldosterone and total and active plasma renin levels 12 to 24 h after the last dose. The maintenance of the BP reductions at this time indicated that blocking of the effects of aldosterone by eplerenone persists beyond 24 h. Changes in BP and hormone levels were greater with twice daily 50 mg of spironolactone than with twice daily 50 mg or daily 100 mg of eplerenone, suggesting that on a molecular weight basis eplerenone is 50% to 75% as potent as spironolactone.
The adverse event profile was similar in eplerenone and placebo. Only one serious drug-related adverse eventchest pain in the daily 50-mg eplerenone group-was reported in the study. The incidence of adverse events was also comparable between the eplerenone and spironolactone groups. No adverse effects were observed in liver function within any treatment group. Although both eplerenone and spironolactone increased mean serum potassium levels, only two eplerenone-treated patients were judged to have clinically significant changes. A recent study of patients with heart failure found that the overall incidence of adverse events and discontinuation because of adverse events was comparable between spironolactone and placebo groups. 1 However, a significantly greater number of spironolactone-treated men experienced gynecomastia or breast pain. 1 Gynecomastia also has been reported in 6.9% of hypertensive men treated with daily doses of 50 mg or less of spironolactone. 16 In the present 8-week study, the incidence of impotence in the eplerenone-treated patients was comparable to that of placebo, no cases of gynecomastia were noted in any of the eplerenone groups, and there were no reports of menstrual abnormalities in the eplerenone-treated patients. Such data suggest a lack of interaction between eplerenone and sex hormone receptors. In the twice daily 200-mg eplerenone group, significant increases in thyroid-stimulating hormone, although within the normal range, were observed. No changes were observed in the daily 400-mg dose group. Differences observed in serum thyroxine levels were not significant, suggesting that changes in thyroidstimulating hormone in the twice daily 200-mg eplerenone group were not clinically relevant.
In conclusion, 50 to 400 mg of eplerenone given once daily or in divided doses is a potent aldosterone receptor antagonist that provides a dose-related reduction in SBP and DBP. Eplerenone was well tolerated, the incidence of adverse events was comparable to placebo, and no progestational or antiandrogenic side effects were observed. Therefore, eplerenone was shown to be a highly selective aldosterone blocker, with 24-h therapeutic effects on BP and the RAAS system in patients with mild-to-moderate hypertension.
